Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1681 to 1695 of 9102 results

  1. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.

    Technology appraisal guidance
    Published
    20 November 2019
    View recommendations

    Sections for TA612

  2. Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

    Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    19 February 2020
    View recommendations

    Sections for TA624

  3. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

    Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.

    Technology appraisal guidance
    Published
    20 March 2019
    View recommendations

    Sections for TA569

  4. Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.

    Technology appraisal guidance
    Published
    7 March 2018
    View recommendations

    Sections for TA509

  5. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    5 June 2019
    View recommendations

    Sections for TA583

  6. Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.

    Technology appraisal guidance
    Published
    23 July 2014
    View recommendations

    Sections for TA316

  7. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    27 August 2014
    View recommendations

    Sections for TA320

  8. Naloxegol for treating opioid‑induced constipation (TA345)

    Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA345

  9. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

    Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA347

  10. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date:  17 September 2026

    Technology appraisal guidance
    In development

  11. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]

    In development Reference number: GID-TA11488 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6753]

    Awaiting development Reference number: GID-TA11973 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]

    In development Reference number: GID-TA11959 Expected publication date:  17 June 2027

    Technology appraisal guidance
    In development

  14. Enlicitide decanoate for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6656]

    Awaiting development Reference number: GID-TA11871 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date: TBC

    Technology appraisal guidance
    In development